Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8446302 | 0.93 | CYP19A1 (0.86) | CYP19A1STS | |
| SCHEMBL12189187 | 0.89 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL2700646 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL2702534 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL544997 | 0.86 | CYP19A1 (1.00) | CYP19A1STS | |
| SCHEMBL8446035 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL8445354 | 0.86 | CYP19A1 (1.00) | CYP19A1STS | |
| SCHEMBL3233064 | 0.86 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL5035869 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL8445536 | 0.86 | CYP19A1 (0.76) | CYP19A1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120230914-A1 | LABELING COMPOUND FOR PET | RIKEN (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-0641785-B1 | TRIAZOLYLATED TERTIARY AMINE COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 1999-10-27 | — | — | EP | disclosed |
| US-5674886-A | AROMATASE INHIBITOR; BREAST CANCER; UROGENITAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-07 | — | — | US | disclosed |
| EP-0641785-A1 | TRIAZOLYLATED TERTIARY AMINE COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120230914-A1 | LABELING COMPOUND FOR PET | CYP19A1, CYP2F1, CYP4F11 | CYP19A1 1/4885STS 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.